PACB vs RCL · rev $76.2M vs P/E 26, rev $9.28B
Pacific Biosciences of California (PACB) versus Royal Caribbean Cruises Ltd (RCL) — a side-by-side from cached financials, not a winner call.
Pacific Biosciences of California (PACB) is a medical devices company listed on US.
Royal Caribbean Cruises Ltd (RCL) is a travel services company listed on US.
Latest reported PACB revenue for 2026-06-30 was $76.2M. Net income was -$53.0M. PACB currently screens at market cap $387.1M.
Latest reported RCL revenue for 2026-06-30 was $9.28B. Net income was $2.07B. RCL currently screens at market cap $85.57B and trailing P/E 25.7.
PACB currently screens at market cap $387.1M. RCL currently screens at market cap $85.57B and trailing P/E 25.7.
Not investment advice. Open the PACB and RCL stock pages for the full models.
Not investment advice.